OBJECTIVE: To determine the functional and cognitive outcomes of patients with prolonged refractory status epilepticus (PRSE) lasting 7 or more days despite the use of anesthetic agents for seizure suppression. DESIGN: Retrospective analysis. SETTING: St Mary's Hospital, Mayo Clinic, Rochester, Minnesota. PARTICIPANTS: Fourteen patients with PRSE. INTERVENTION: Hospital follow-up interview. MAIN OUTCOME MEASURES: Survival rate of PRSE and functional and cognitive outcome of surviving patients based on the modified Rankin Scale (mRS) and Telephone Interview for Cognitive Status (TICS). RESULTS: Forty-three percent of patients (6 of 14) died during hospitalization for PRSE, and 57% (8 of 14) had died by the last follow-up. Of the 6 surviving patients, 4 showed improvement and 2 showed no change in mRS score (median mRS change, -1; range, 0 to -3). Owing to preexisting cognitive deficits, 1 patient could not complete the TICS. The 5 remaining patients scored a median of 34 on the TICS (range, 30-37; reference TICS score, >or=31; maximum TICS score, 41). Age, sex, PRSE duration, and etiology were not associated with chance of survival. CONCLUSIONS: Despite the high mortality rate, survival with meaningful functional and cognitive recovery is possible after PRSE. Prolonged duration of status epilepticus alone should not be considered a reason to discontinue treatment.
OBJECTIVE: To determine the functional and cognitive outcomes of patients with prolonged refractory status epilepticus (PRSE) lasting 7 or more days despite the use of anesthetic agents for seizure suppression. DESIGN: Retrospective analysis. SETTING: St Mary's Hospital, Mayo Clinic, Rochester, Minnesota. PARTICIPANTS: Fourteen patients with PRSE. INTERVENTION: Hospital follow-up interview. MAIN OUTCOME MEASURES: Survival rate of PRSE and functional and cognitive outcome of surviving patients based on the modified Rankin Scale (mRS) and Telephone Interview for Cognitive Status (TICS). RESULTS: Forty-three percent of patients (6 of 14) died during hospitalization for PRSE, and 57% (8 of 14) had died by the last follow-up. Of the 6 surviving patients, 4 showed improvement and 2 showed no change in mRS score (median mRS change, -1; range, 0 to -3). Owing to preexisting cognitive deficits, 1 patient could not complete the TICS. The 5 remaining patients scored a median of 34 on the TICS (range, 30-37; reference TICS score, >or=31; maximum TICS score, 41). Age, sex, PRSE duration, and etiology were not associated with chance of survival. CONCLUSIONS: Despite the high mortality rate, survival with meaningful functional and cognitive recovery is possible after PRSE. Prolonged duration of status epilepticus alone should not be considered a reason to discontinue treatment.
Authors: Andres Fernandez; Hector Lantigua; Christine Lesch; Belinda Shao; Brandon Foreman; J Michael Schmidt; Lawrence J Hirsch; Stephan A Mayer; Jan Claassen Journal: Neurology Date: 2013-12-20 Impact factor: 9.910
Authors: Dominik Madžar; Anna Geyer; Ruben U Knappe; Stephanie Gollwitzer; Joji B Kuramatsu; Stefan T Gerner; Hajo M Hamer; Hagen B Huttner Journal: J Neurol Date: 2016-01-02 Impact factor: 4.849
Authors: Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover Journal: Neurocrit Care Date: 2013-04 Impact factor: 3.210
Authors: Ikuko Laccheo; Hasan Sonmezturk; Amar B Bhatt; Luke Tomycz; Yaping Shi; Marianna Ringel; Gina DiCarlo; DeAngelo Harris; John Barwise; Bassel Abou-Khalil; Kevin F Haas Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210